The evaluation of Mastodinon efficiency in treatment of hyperprolactinemic syndrome
- 作者: Vishnevsky A.1, Safronnikova N.1, Melnikova N.1, Grigorieva T.1
-
隶属关系:
- Center for Preventive Medicine of the Association of Gynecologic Oncologists
- 期: 卷 49, 编号 1 (2000)
- 页面: 39-41
- 栏目: Original Research
- URL: https://journals.rcsi.science/jowd/article/view/88937
- DOI: https://doi.org/10.17816/JOWD88937
- ID: 88937
如何引用文章
全文:
详细
The clinical efficiency of Mastodinon (“Bionorica”) is studied in management of 33 patients (average age 34,6 years) with different menstrual disfunctions and dysmenorrhea. In 13 patients these disturbances coexisted with hyperprolactinemia.
As a result of 3-month treatment with Mastodinon we noted the normalization of menstrual function in 13 of 17 patients, and the decrease in prolactin serum levels on 10 of 13 women. The prolactin decrease was followed by increase in luteinizing hormone and progesteron, as chosen for ovulatory cycle.
It is found that Mastodinon has the properties of dopaminomimetics and can be concerned as the alternative for synthetic dopaminergic drug therapy (Bromocriptine etc.).
作者简介
A. Vishnevsky
Center for Preventive Medicine of the Association of Gynecologic Oncologists
编辑信件的主要联系方式.
Email: info@eco-vector.com
俄罗斯联邦, St. Petersburg
N. Safronnikova
Center for Preventive Medicine of the Association of Gynecologic Oncologists
Email: info@eco-vector.com
俄罗斯联邦, St. Petersburg
N. Melnikova
Center for Preventive Medicine of the Association of Gynecologic Oncologists
Email: info@eco-vector.com
俄罗斯联邦, St. Petersburg
T. Grigorieva
Center for Preventive Medicine of the Association of Gynecologic Oncologists
Email: info@eco-vector.com
俄罗斯联邦, St. Petersburg